Clinical Trial

A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how well laroprovstat and ezetimibe combined in a single tablet to be taken by mouth works and what the body does to the drug (pharmacokinetics) compared with laroprovstat and ezetimibe individual tablets to be taken by mouth (relative bioavailability) as well as to see if there is any effect of eating compared to fasting (food effect) in healthy adults.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-07-29
critical Recruitment opened 2026-06-17
Trial Details
NCT Number NCT07622433
Lead Sponsor AstraZeneca
Conditions Healthy Participants
Enrollment 18 participants
Start Date 2026-06-10
Primary Completion 2026-09-07 (estimated)
Study Completion 2026-09-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-28